-
2024-519871-24-00
10
2025-11-11
Breast cancer
-
2024-520156-22-00
4
2025-10-08
Metastatic hormone-sensitive prostate cancer
-
2024-519152-82-00
5
2025-09-03
Relapsed/Refractory Follicular Lymphoma
-
2024-518154-16-00
5
2025-08-27
non-small cell lung cancer
-
2024-520359-26-00
4
2025-08-20
Immune Thrombocytopenia (ITP)
-
2024-516633-12-00
5
2025-06-30
Locally advanced/ metastatic gastroesophageal junction and gastric can
-
2023-510026-32-00
5
2025-06-11
Generalized Myasthenia Gravis
-
2024-515593-27-00
5
2025-05-08
relapsed or refractory mantle cell lymphoma (R/R MCL)
-
2023-509632-26-00
9
2025-02-11
Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
-
2024-515457-21-00
3
2024-12-30
Non-Hodgkin lymphoma and chronic lymphocytic leukemia
-
2024-513098-31-00
4
2024-11-14
Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
-
2023-504724-25-00
5
2024-10-16
Primary Myelofibrosis
-
2024-511688-27-00
4
2024-09-19
Myelofibrosis
-
2023-508005-24-00
5
2024-08-01
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2023-507407-59-00
5
2024-07-04
Chronic Obstructive Pulmonary Disease (COPD)
-
2022-502113-28-00
5
2024-02-01
Follicular lymphoma
-
2022-503092-28-00
5
2024-01-08
Relapsed/Refractory Follicular Lymphoma
-
2023-510541-25-00
1
2023-10-09
Relapsed/Refractory B-cell Malignancies
-
2023-507396-21-00
4
2023-03-16
transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic
-
2023-507699-38-00
5
2022-08-30
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2024-510690-16-00
5
2022-01-31
Relapsed/refractory follicular lymphoma
-
2024-515273-10-00
7
2021-10-19
Relapsed or refractory Multiple Myeloma (r/r MM)
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2024-512671-12-00
10
2021-03-05
Unresectable head and neck squamous cell carcinoma, metastatic head an